Scholar Rock Q1 net loss $56.9M ($0.59/shr); Phase 3 SMA data on track for Q4 2024

Scholar Rock Holding Corp

2024-Q1 EPS reported -$0.59

Net loss $56.9M ($0.59/shr) vs $39.4M ($0.49) Q1 2023; no revenue; R&D up 45% to $43.1M.
Cash $238M as of March 31, 2024; expected to fund operations into 2H 2025.
Phase 3 SAPPHIRE top-line data for apitegromab in SMA on track for Q4 2024; potential commercial launch in 2025 if successful.
Initiating Phase 2 proof-of-concept trial of apitegromab + GLP-1 RA in obesity in June 2024; data expected mid-2025.
SRK-181 data selected for oral presentation at ASCO 2024; SRK-439 preclinical data at ADA 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Scholar Rock Holding Corp reported the quarter ended March 31, 2024 results: revenue no revenue, net income net loss was $56.9 million or $0.59 per share, EPS $0.59 per share.

Period: the quarter ended March 31, 2024
Revenue: no revenue
Net income: net loss was $56.9 million or $0.59 per share
EPS: $0.59 per share
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2024, net loss was $56.9 million or $0.59 per share compared to a net loss of $39.4 million or $0.49 per share for the quarter ended March 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-006906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.